Cytomegalovirus monitoring by polymerase chain reaction of whole blood samples from patients undergoing autologous bone marrow or peripheral blood progenitor cell transplantation

The Journal of Infectious Diseases
H HebartH Einsele

Abstract

Sensitive screening for cytomegalovirus (CMV) by polymerase chain reaction (PCR) following autologous bone marrow or peripheral blood progenitor cell transplantation has not been evaluated. In a three-center study, 98 autograft transplant recipients were prospectively screened for CMV infection by PCR and culture techniques. At a median of 20 days (range, 3-28) after transplantation, 21 (39.6%) of 53 CMV-seronegative patients were PCR positive for CMV, and at a median of 17 days (range, 7-84) after transplantation, 19 (42.2%) of 45 CMV-seropositive patients were PCR positive for CMV. Low-level DNAemia (1-10 fg CMV DNA/mL blood) occurred for 1 week in 31 patients but was never associated with CMV disease. Of 9 patients who presented with at least two consecutive positive PCR results, 1 developed CMV pneumonia. No patients died because of CMV disease. Screening for CMV infection by PCR had a negative predictive value of 100% (as also observed after allogeneic transplantation), but its positive predictive value was significantly lower.

Citations

Jun 29, 2001·Transplant Infectious Disease : an Official Journal of the Transplantation Society·M Boeckh
Nov 1, 2002·Journal of Clinical Microbiology·Adriana WeinbergRoger Giller
May 24, 2014·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·J-H KoJ-H Song
Jan 18, 2011·Hematology/oncology Clinics of North America·Per LjungmanMichael Boeckh
May 15, 2010·Infectious Disease Clinics of North America·Per LjungmanMichael Boeckh
May 8, 2013·British Journal of Haematology·Vincent EmeryUNKNOWN UK Virology Network
May 25, 2005·Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology·P Martín-DávilaS Moreno
Jun 3, 2004·Human Immunology·Holger Hebart, Hermann Einsele
Jul 18, 2002·International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases·Massimo FranchiniFabio Benedetti
Nov 30, 2004·The Lancet Infectious Diseases·Maher K Gandhi, Rajiv Khanna
Apr 6, 2004·Clinics in Chest Medicine·Kenneth T YenCharles D Burger
Mar 6, 2004·The Journal of Infection·L C SpanoJ P G Leite
Feb 15, 2002·British Journal of Haematology·K S Peggs, S Mackinnon
Sep 27, 2005·American Journal of Hematology·Kasem SirithanakulAyman O Soubani

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.